Tsuji Kenji, Nakanoh Hiroyuki, Fukushima Kazuhiko, Kitamura Shinji, Wada Jun
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
Program in Membrane Biology, Center for Systems Biology, Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Diagnostics (Basel). 2023 Sep 9;13(18):2893. doi: 10.3390/diagnostics13182893.
Acute kidney injury (AKI) is a clinical syndrome where a rapid decrease in kidney function and/or urine output is observed, which may result in the imbalance of water, electrolytes and acid base. It is associated with poor prognosis and prolonged hospitalization. Therefore, an early diagnosis and treatment to avoid the severe AKI stage are important. While several biomarkers, such as urinary L-FABP and NGAL, can be clinically useful, there is still no gold standard for the early detection of AKI and there are limited therapeutic options against AKI. miRNAs are non-coding and single-stranded RNAs that silence their target genes in the post-transcriptional process and are involved in a wide range of biological processes. Recent accumulated evidence has revealed that miRNAs may be potential biomarkers and therapeutic targets for AKI. In this review article, we summarize the current knowledge about miRNAs as promising biomarkers and potential therapeutic targets for AKI, as well as the challenges in their clinical use.
急性肾损伤(AKI)是一种临床综合征,表现为肾功能和/或尿量迅速下降,这可能导致水、电解质和酸碱平衡失调。它与预后不良和住院时间延长有关。因此,早期诊断和治疗以避免进入严重AKI阶段很重要。虽然几种生物标志物,如尿L-FABP和NGAL,在临床上可能有用,但目前仍没有早期检测AKI的金标准,且针对AKI的治疗选择有限。微小RNA(miRNA)是一类非编码单链RNA,在转录后过程中使靶基因沉默,并参与广泛的生物学过程。最近积累的证据表明,miRNA可能是AKI的潜在生物标志物和治疗靶点。在这篇综述文章中,我们总结了关于miRNA作为AKI有前景的生物标志物和潜在治疗靶点的现有知识,以及它们在临床应用中的挑战。